Skip to main content
. Author manuscript; available in PMC: 2023 Mar 18.
Published in final edited form as: Med Decis Making. 2022 Dec 13;43(3):337–349. doi: 10.1177/0272989X221143058

Table 1.

Reaching the recommended treatment, via a prognostic model, between four options: placebo, glatiramer acetate, dimethyl fumarate, and natalizumab. Hypothetical Example in relapsing-remitting multiple sclerosis.

Treatment Placebo Glatiramer acetate Dimethyl
fumarate		 Natalizumab
Predicted risk to relapse within two years (Ri,j) 75% 66% 52% 44%
Predicted risk difference vs placebo (RDi,j) - 9% 23% 31%
Threshold value for treatment j (Tj) 10% 10% 20%
RDi,j–Tj −1% 12% 11%
Recommended treatment via the prediction model Dimethyl fumarate